Quantitation of cytokine- and lipopolysaccharide (LPS)-mediated regulation of MEFV mRNA levels in peripheral blood myelomonocytic cells.

Autoradiograms of results obtained with RNase protection assay of total RNA derived from peripheral blood leukocytes by using an MEFVgene-specific riboprobe and 2 housekeeping gene–specific riboprobes (L32 and GAPDH) are shown. Baseline levels ofMEFV mRNA in resting cells before stimulation (untreated) are shown in each panel. (A) Products from monocytes treated for 24 hours in vitro with interleukin (IL) 10, transforming growth factor β (TGF-β), IL-4, interferon (IFN) γ, LPS, or tumor necrosis factor. (B) Products from monocytes treated with LPS and IFN-γ alone and with LPS and IFN-γ in combination with either IL-4, IL-10, or TGF-β. (C) Time course of MEFV induction in monocytes treated with IFN-γ for 0.5, 1, 4, 12, and 24 hours. (D) Products from untreated monocytes and monocytes treated with IFN-γ and both IFN-γ and cycloheximide. (E) Time course of MEFV induction in monocytes treated with LPS for 0.5, 1, 4, 12, and 24 hours. (F) Time course of MEFVinduction in monocytes treated with IFN-α for 0.5, 1, 4, and 12 hours. (G) Products from granulocytes treated with colchicine, IFN-γ, IFN-α, IFN-γ and colchicine, and IFN-α and colchicine.